Pharmacogenomic Research in Korean Patients With Hepatitis C

The aim of this study is to investigate the relationships between drug response and the host genetic factors, viral factors and clinical factors in chronic hepatitis C patients (HCV). And thus, the investigators are trying to develop the pharmacogenomic guideline in the Korean patients with HCV.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Hepatitis C Blood-Borne Infections Chronic Disease Communicable Diseases Digestive System Diseases Disease Attributes Flaviviridae Infections Hepatitis Hepatitis C Hepatitis C, Chronic Hepatitis, Chronic Hepatitis, Viral, Human Infections Liver Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms RNA Virus Infections Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Inje University

Busan, 633-165, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Hepatitis C virus infected patients

Exclusion criteria

Patients who infected Hepatitis B virus or Human immunodeficiency virus
HCV infected patients previously treated with antiviral drugs
Patients had a history of autoimmune hemolytic anemia

Treatment and study plan

Primary outcomes

Sustained virological response (SVR)

Time frame: 24 weeks after the end of treatment

Undetectable HCV RNA in serum ( <15 IU/ml ) 24 weeks after the end of treatment

Secondary outcomes

Anemia

Time frame: 4 weeks after start of treatment
- a reduction in Hemoglobin of >3.0 g/dL
- a reduction in Hemoglobin levels to 10.0g/dL.

Sponsors and collaborators

Lead sponsor

Inje University

Other

Registry information

Official study title

Pharmacogenomic Research for Prediction of Drug Response in Korean Patients With Hepatitis C

Important dates

Study start: 2011
Primary completion: 2013
Study completion: 2013
First posted: Oct 17, 2011
Registry last updated: Jun 3, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed